Вы искали: knoglemarvshypoplasi (Датский - Английский)

knoglemarvshypoplasi
hypoplasia of the bone marrow

leukopoeni, eosinofili, knoglemarvshypoplasi.
rare: severe anaemia.

trombocytopeni og pancytopeni (med knoglemarvshypoplasi) sjældne:
thrombocyopenia and pancytopenia (with marrow hypoplasia) rare:

ikke almindelig: trombocytopeni og pancytopeni (med knoglemarvshypoplasi)
uncommon: thrombocyopenia and pancytopenia (with marrow hypoplasia)

anamnese med bloddyskrasier, for eksempel knoglemarvshypoplasi, leukopeni, trombocytopeni eller signifikant anæmi.
pre-existing blood dyscrasias, such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anaemia.

der blev ikke observeret nogen lægemiddelbaserede bivirkninger i form af pancytopeni/knoglemarvshypoplasi hos førstegangsbehandlede patienter behandlet med mabcampath.
no adverse drug reactions of pancytopenia/marrow hypoplasia were observed in first-line patients treated with mabcampath.

anæmi, leukopeni, trombocytopeni, eosinofili og knoglemarvshypoplasi er set i sjældne tilfælde (se pkt.4. 8) .
anaemia, leucopenia, thrombocytopenia, eosinophilia and bone marrow hypoplasia have been reported rarely (see section 4.8) .

alle ændringer, dvs. leukopeni, anæmi, knoglemarvshypoplasi, atrofiske forandringer i lymfatiske og hæmatopoietiske væv og mave-tarm-kanalen, var reversible inden for 9 uger efter seponering.
all changes, i.e., leucopenia, anaemia, bone marrow hypoplasia, atrophic changes in the lymphatic and haematopoietic tissues and the gastrointestinal tract, were reversible within 9 weeks of drug withdrawal.